C
국전
307750KOSDAQ51.0 / 100
Reference Date: 2026-09-08
Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 7.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Kukjeon Pharm operates two main business segments: the pharmaceutical division, focusing on the synthesis and distribution of active pharmaceutical ingredients (APIs), and the materials division, developing high-performance specialty materials for advanced industries such as OLEDs, semiconductors, and AI. The company is strengthening its competitiveness through new drug development and global market expansion.
Number of Employees
172people
Average Salary
68.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
1.30Industry Average 1.202.5Point
Higher than industry avg (caution)
ROE
-4.99Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
18.00Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.0 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲3.9% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼446.9% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 0.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (13%, downtrend)
Current 2,310Won52-week high 5,54052-week low 1,800
1-month return5.0Point
1m +7.69% (rising)
Volume trend6.0Point
Volume surge
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-09-03
- Neutral신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득2026-08-27
- Neutral주식등의대량보유상황보고서(일반)2026-08-24
- Neutral주식등의대량보유상황보고서(일반)2026-08-13
- Neutral반기보고서 (2026.06)2026-08-13